Andere Sprachen Apellis Pharmaceuticals, Inc.

Aktien

A2JAAW

US03753U1060

APLS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 23.04.2024			% 5 Tage	% 1. Jan.
48.7 ^USD	+2.23%		-6.02%	-18.64%

17.04.	APELLIS PHARMACEUTICALS, INC. : Wedbush bleibt neutral	ZM
09.04.	Apellis Pharmaceuticals Insider verkaufte Aktien im Wert von $3.743.605, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results	23.04.
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	09.04.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.04.
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	01.04.
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	21.03.
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	20.03.
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	14.03.
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	11.03.
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11.03.
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11.03.
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	11.03.
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	07.03.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.03.
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing	05.03.
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04.03.
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	27.02.
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M	27.02.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	27.02.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Apellis Pharmaceuticals, Inc.

Aktien

A2JAAW

US03753U1060

APLS

Andere Sprachen

Filter